Novel fast pathogen diagnosis method for severe pneumonia patients in the intensive care unit: randomized clinical trial

Abstract

Background:

Severe pneumonia is one of the common acute diseases caused by pathogenic bacteria infection, especially by pathogenic bacteria, leading to sepsis with a high morbidity and mortality rate. However, the existing bacteria cultivation method cannot satisfy current clinical needs requiring rapid identification of bacteria strain for antibiotic selection. Therefore, developing a sensitive liquid biopsy system demonstrates the enormous value of detecting pathogenic bacterium species in pneumonia patients.

Methods:

In this study, we developed a tool named Species-Specific Bacterial Detector (SSBD, pronounce as "speed") for detecting selected bacterium. Newly designed diagnostic tools combining specific DNA-tag screened by our algorithm and CRISPR/Cas12a, which were first tested in the lab to confirm the accuracy, followed by validating its specificity and sensitivity via applying on bronchoalveolar lavage fluid (BALF) from pneumonia patients. In the validation I stage, we compared the SSBD results with traditional cultivation results. In the validation II stage, a randomized and controlled clinical trial was completed at the ICU of Nanjing Drum Tower Hospital to evaluate the benefit SSBD brought to the treatment.

Results:

In the validation stage I, 77 BALF samples were tested, and SSBD could identify designated organisms in 4 hours with almost 100% sensitivity and over 87% specific rate. In validation stage II, the SSBD results were obtained in 4 hours, leading to better APACHE II scores (p=0.0035, ANOVA test). Based on the results acquired by SSBD, cultivation results could deviate from the real pathogenic situation with polymicrobial infections. In addition, nosocomial infections were found widely in ICU, which should deserve more attention.

Funding:

National Natural Science Foundation of China. The National Key Scientific Instrument and Equipment Development Project. Project number: 81927808.

Clinical trial:

This study was registered at ClinicalTrilas.gov (NCT04178382).

Data availability

All data generated or analysed during this study are included in the manuscript and supporting file; Source Data files have been provided for Figures 3-5, Appendix figures 2-5, and Appendix tables 3-9.

Article and author information

Author details

  1. Yan Wang

    Department of Critical Care Medicine, Nanjing University, Nanjing, China
    Competing interests
    The authors declare that no competing interests exist.
  2. Xiaohui Liang

    The State Key Laboratory of Pharmaceutical Biotechnology, Nanjing University, Nanjing, China
    Competing interests
    The authors declare that no competing interests exist.
  3. Yuqian Jiang

    The State Key Laboratory of Pharmaceutical Biotechnology, Nanjing University, Nanjing, China
    Competing interests
    The authors declare that no competing interests exist.
  4. Danjiang Dong

    Department of Critical Care Medicine, Nanjing University, Nanjing, China
    Competing interests
    The authors declare that no competing interests exist.
  5. Cong Zhang

    The State Key Laboratory of Pharmaceutical Biotechnology, Nanjing University, Nanjing, China
    Competing interests
    The authors declare that no competing interests exist.
  6. Tianqiang Song

    The State Key Laboratory of Pharmaceutical Biotechnology, Nanjing University, Nanjing, China
    Competing interests
    The authors declare that no competing interests exist.
  7. Ming Chen

    Department of Critical Care Medicine, Nanjing University, Nanjing, China
    Competing interests
    The authors declare that no competing interests exist.
  8. Yong You

    Department of Critical Care Medicine, Nanjing University, Nanjing, China
    Competing interests
    The authors declare that no competing interests exist.
  9. Han Liu

    Department of Critical Care Medicine, Nanjing Medical University, Nanjing, China
    Competing interests
    The authors declare that no competing interests exist.
  10. Min Ge

    Department of Cardiothoracic Surgery Intensive Care Unit, Nanjing University, Nanjing, China
    Competing interests
    The authors declare that no competing interests exist.
  11. Haibin Dai

    Department of Neurosurgery Intensive Care Unit, Nanjing University, Nanjing, China
    Competing interests
    The authors declare that no competing interests exist.
  12. Fengchan Xi

    Research Institute of General Surgery, Nanjing University, Nanjing, China
    Competing interests
    The authors declare that no competing interests exist.
  13. Wanqing Zhou

    Department of Laboratory Medicine, Nanjing University, Nanjing, China
    Competing interests
    The authors declare that no competing interests exist.
  14. Jian-Qun Chen

    The State Key Laboratory of Pharmaceutical Biotechnology, Nanjing University, Nanjing, China
    Competing interests
    The authors declare that no competing interests exist.
  15. Qiang Wang

    The State Key Laboratory of Pharmaceutical Biotechnology, Nanjing University, Nanjing, China
    For correspondence
    wangq@nju.edu.cn
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-2907-9851
  16. Qihan Chen

    The State Key Laboratory of Pharmaceutical Biotechnology, Nanjing University, Nanjing, China
    For correspondence
    chenqihan@nju.edu.cn
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-0062-8434
  17. Wenkui Yu

    Department of Critical Care Medicine, Nanjing University, Nanjing, China
    For correspondence
    yudrnj@nju.edu.cn
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-4218-0321

Funding

National Natural Science Foundation of China (The National Key Scientific Instrument and Equipment Development Project,81927808)

  • Wenkui Yu

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Ethics

Human subjects: We acquired the ethics approval (2019-197-01) from the ethics committee of Nanjing Drum Tower Hospital Affiliated to Nanjing University Medical School in July 2019, registered and posted the complete research protocol, informed consent, subject materials, case report form, researcher manual, the introduction of main researchers and other information in Chinese. Later on, this study was registered in English at ClinicalTrilas.gov (NCT04178382) in November 2019.

Copyright

© 2022, Wang et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 993
    views
  • 318
    downloads
  • 3
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Yan Wang
  2. Xiaohui Liang
  3. Yuqian Jiang
  4. Danjiang Dong
  5. Cong Zhang
  6. Tianqiang Song
  7. Ming Chen
  8. Yong You
  9. Han Liu
  10. Min Ge
  11. Haibin Dai
  12. Fengchan Xi
  13. Wanqing Zhou
  14. Jian-Qun Chen
  15. Qiang Wang
  16. Qihan Chen
  17. Wenkui Yu
(2022)
Novel fast pathogen diagnosis method for severe pneumonia patients in the intensive care unit: randomized clinical trial
eLife 11:e79014.
https://doi.org/10.7554/eLife.79014

Share this article

https://doi.org/10.7554/eLife.79014

Further reading

    1. Medicine
    2. Neuroscience
    Emily M Adamic, Adam R Teed ... Sahib Khalsa
    Research Article

    Interactions between top-down attention and bottom-up visceral inputs are assumed to produce conscious perceptions of interoceptive states, and while each process has been independently associated with aberrant interoceptive symptomatology in psychiatric disorders, the neural substrates of this interface are unknown. We conducted a preregistered functional neuroimaging study of 46 individuals with anxiety, depression, and/or eating disorders (ADE) and 46 propensity-matched healthy comparisons (HC), comparing their neural activity across two interoceptive tasks differentially recruiting top-down or bottom-up processing within the same scan session. During an interoceptive attention task, top-down attention was voluntarily directed towards cardiorespiratory or visual signals. In contrast, during an interoceptive perturbation task, intravenous infusions of isoproterenol (a peripherally-acting beta-adrenergic receptor agonist) were administered in a double-blinded and placebo-controlled fashion to drive bottom-up cardiorespiratory sensations. Across both tasks, neural activation converged upon the insular cortex, localizing within the granular and ventral dysgranular subregions bilaterally. However, contrasting hemispheric differences emerged, with the ADE group exhibiting (relative to HCs) an asymmetric pattern of overlap in the left insula, with increased or decreased proportions of co-activated voxels within the left or right dysgranular insula, respectively. The ADE group also showed less agranular anterior insula activation during periods of bodily uncertainty (i.e. when anticipating possible isoproterenol-induced changes that never arrived). Finally, post-task changes in insula functional connectivity were associated with anxiety and depression severity. These findings confirm the dysgranular mid-insula as a key cortical interface where attention and prediction meet real-time bodily inputs, especially during heightened awareness of interoceptive states. Furthermore, the dysgranular mid-insula may indeed be a ‘locus of disruption’ for psychiatric disorders.

    1. Medicine
    Yanling Huang, Haocong Mo ... Geyang Xu
    Research Article

    Glucagon-like peptide 1 (GLP-1) is a gut-derived hormone secreted by intestinal L cells and vital for postprandial glycemic control. As open-type enteroendocrine cells, whether L cells can sense mechanical stimuli caused by chyme and thus regulate GLP-1 synthesis and secretion is unexplored. Molecular biology techniques revealed the expression of Piezo1 in intestinal L cells. Its level varied in different energy status and correlates with blood glucose and GLP-1 levels. Mice with L cell-specific loss of Piezo1 (Piezo1 IntL-CKO) exhibited impaired glucose tolerance, increased body weight, reduced GLP-1 production and decreased CaMKKβ/CaMKIV-mTORC1 signaling pathway under normal chow diet or high-fat diet. Activation of the intestinal Piezo1 by its agonist Yoda1 or intestinal bead implantation increased the synthesis and secretion of GLP-1, thus alleviated glucose intolerance in diet-induced-diabetic mice. Overexpression of Piezo1, Yoda1 treatment or stretching stimulated GLP-1 production and CaMKKβ/CaMKIV-mTORC1 signaling pathway, which could be abolished by knockdown or blockage of Piezo1 in primary cultured mouse L cells and STC-1 cells. These experimental results suggest a previously unknown regulatory mechanism for GLP-1 production in L cells, which could offer new insights into diabetes treatments.